Genomic characterization and pre-clinical evaluation of a new polyvalent lytic Loughborough phage
Applied Microbiology and Biotechnology · 2025
DOI: 10.1007/s00253-025-13559-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, 2025. Verfasst von Mahmoud M Sherif und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Faculty of Pharmacy, Sixth of October City, Ahram Canadian University, Giza, 12451, Egypt. Hauptthemen laut MEDLINE: Genome, Viral, Phage Therapy, Acinetobacter baumannii, Acinetobacter Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ain Shams University.
Abstract (Originalsprache)
Carbapenem-resistant Acinetobacter baumannii (CRAB) has become a critical concern that necessitates the development of novel antimicrobial approaches. One of the most promising innovative approaches for combating CRAB infections is using effective and lytic bacteriophages (phages), known as phage therapy. Therefore, we recovered and characterized a polyvalent lytic Salmonella_phage_VB_ST-SA173, producing lytic activity against 6 CRAB clinical isolates and 3 multidrug-resistant (MDR) Salmonella serovars. Throughout pH 2–10, and thermal stability at up to 60 °C, the phage maintained its stability and lytic activity against the tested isolates. The presence of a tailed phage with a characteristic prolate head and a contractile tail was detected by the transmission electron microscope (TEM). According to the Oxford nanopore sequencing data, the genome of Salmonella_phage_VB_ST-SA173 was 53,636 bp in size, contained 45.9% G + C, and had 53 opening reading frames (ORFs). According to the TEM, ORFs, and BLASTn analysis findings, it was proved that the Salmonella_phage_VB_ST-SA173 belongs to the Loughboroughvirus genus. The efficacy of the phage-formulated Carbopol 940 hydrogel in wound healing was assessed preclinically in an infected burn wound animal model with a CRABa clinical isolate. The survival rate was enhanced in the phage-treated group compared to the untreated control groups. Histopathological analysis showed improved wound healing in the form of apparently healthy skin with apparently normal epidermal and dermis layers. In conclusion, depending on its in vitro and physicochemical traits, the phage-loaded hydrogel is expected to be a promising candidate for clinical trials against human CRAB-related skin infections. Key points • A polyvalent Loughboroughvirus phage showed lytic activity against CRAB and Salmonella serovars. • The phage showed stability at a wide range of pH and temperature. • The phage hydrogel enhanced healing in the burn-wound animal model infected with CRABa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Faculty of Pharmacy, Sixth of October City, Ahram Canadian University, Giza, 12451, Egypt.
- Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt.
- Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt. aboshanab2012@pharma.asu.edu.eg.
Förderung
- Ain Shams University
Zitieren
APA
Sherif, M. M., Abdelaziz, N. A., Saleh, S. E., & Aboshanab, K. M. (2025). Genomic characterization and pre-clinical evaluation of a new polyvalent lytic Loughborough phage. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-025-13559-2
Vancouver
Sherif MM, Abdelaziz NA, Saleh SE, Aboshanab KM. Genomic characterization and pre-clinical evaluation of a new polyvalent lytic Loughborough phage. Applied Microbiology and Biotechnology. 2025. doi:10.1007/s00253-025-13559-2
BibTeX
@article{Sherif2025,
author = {Sherif, Mahmoud M and Abdelaziz, Neveen A and Saleh, Sarra E and Aboshanab, Khaled M},
title = {Genomic characterization and pre-clinical evaluation of a new polyvalent lytic Loughborough phage},
journal = {Applied Microbiology and Biotechnology},
year = {2025},
doi = {10.1007/s00253-025-13559-2}
}
EUVIMED